Protection against MDMA-induced dopaminergic neurotoxicity in mice by methyllycaconitine: Involvement of nicotinic receptors

Neuropharmacology

Volumn 51, Issue 4, 2006, Pages 885-895

  Chipana, C ^a   Camarasa, J ^a   Pubill, D ^a   Escubedo, E ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

7 Nicotinic receptor; Ecstasy; MDMA; Mice; Neurotoxicity

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 7 NITROINDAZOLE; ALPHA BUNGAROTOXIN; ALPHA TOCOPHEROL; CALCIUM; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE; DOPAMINE TRANSPORTER; METHYLLYCACONITINE; NICOTINIC RECEPTOR; NITRIC OXIDE SYNTHASE; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; RESERPINE; SELEGILINE;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SYNAPTOSOME; CELL ACTIVATION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; GLIA CELL; HYPERTHERMIA; MALE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM;

ACONITINE; ANALYSIS OF VARIANCE; ANIMALS; COCAINE; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; FLOW CYTOMETRY; MALE; MICE; MOTOR ACTIVITY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; RADIOLIGAND ASSAY; REACTIVE OXYGEN SPECIES; RECEPTORS, NICOTINIC; SYNAPTOSOMES; TRITIUM;

EID: 33748165619     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2006.05.032     Document Type: Article

References (31)

1. Arriagada C., Gnino-Subiabre A., Caviedes P., Armero J.M., Caviedes R., and Segura-Aguilar J. Studies of aminochrome toxicity in a mouse derived neuronal cell line: is this toxicity mediated via glutamate transmission?. Amino Acids 18 (2000) 363-373
2. Cadet J.L., Ali S.F., Rothman R.B., and Epstein C.J. Neurotoxicity, drugs and abuse, and the Cu/Zn-superoxide dismutase transgenic mice. Mol. Neurobiol. 11 (1995) 155-163
3. Camarero J., Sanchez V., O'Shea E., Green A.R., and Colado M.I. Studies, using in vivo microdialysis, on the effect of the dopamine uptake inhibitor GBR 12909 on 3,4-methylenedioxymethamphetamine ('ecstasy')-induced dopamine release and free radical formation in the mouse striatum. J. Neurochem. 81 (2002) 961-972
4. Colado M.I., Camarero J., Mechan A.O., Sanchez V., Esteban B., Elliott J.M., and Green A.R. A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') on dopamine neurones in mouse brain. Br. J. Pharmacol. 134 (2001) 1711-1723
5. 3H]methyllycaconitine: a new radioligand for labelling alpha7-type neuronal nicotinic acetylcholine receptors. Neuropharmacology 38 (1999) 679-690
6. Demiryurek A.T., Cakici I., and Kanzik I. Peroxynitrite: a putative cytotoxin. Pharmacol. Toxicol. 82 (1998) 113-117
7. Escubedo E., Guitart L., Sureda F.X., Jimenez A., Pubill D., Pallas M., Camins A., and Camarasa J. Microgliosis and down-regulation of adenosine transporter induced by methamphetamine in rats. Brain Res. 814 (1998) 120-126
8. Escubedo E., Chipana C., Perez-Sanchez M., Camarasa J., and Pubill D. Methyllycaconitine prevents methamphetamine-induced effects in mouse striatum: involvement of alpha7 nicotinic receptors. J. Pharmacol. Exp. Ther. 315 (2005) 658-667
9. Green A.R., Mechan A.O., Elliott J.M., O'Shea E., and Colado M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol. Rev. 55 (2003) 463-508
10. Green A.R., O'Shea E., and Colado M.I. A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response. Eur. J. Pharmacol. 500 (2004) 3-13
11. Guilarte T.R., Nihei M.K., McGlothan J.L., and Howard A.S. Methamphetamine-induced deficits of brain monoaminergic neuronal markers: distal axotomy or neuronal plasticity. Neuroscience 122 (2003) 499-513
12. Gunasekar P.G., Kanthasamy A.G., Borowitz J.L., and Isom G.E. Monitoring intracellular nitric oxide formation by dichlorofluorescin in neuronal cells. J. Neurosci. Methods 61 (1995) 15-21
13. Hansen J.P., Riddle E.L., Sandoval V., Brown J.M., Gibb J.W., Hanson G.R., and Fleckenstein A.E. Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity 166. J. Pharmacol. Exp. Ther. 300 (2002) 1093-1100
14. Jayanthi S., Ladenheim B., Andrews A.M., and Cadet J.L. Overexpression of human copper/zinc superoxide dismutase in transgenic mice attenuates oxidative stress caused by methylenedioxymethamphetamine (Ecstasy). Neuroscience 91 (1999) 1379-1387
15. Kaiser S., and Wonnacott S. Alpha-bungarotoxin-sensitive nicotinic receptors indirectly modulate [(3)H]dopamine release in rat striatal slices via glutamate release. Mol. Pharmacol. 58 (2000) 312-318
16. Kramer H.K., Poblete J.C., and Azmitia E.C. Characterization of the translocation of protein kinase C (PKC) by 3,4-methylenedioxymethamphetamine (MDMA/ecstasy) in synaptosomes: evidence for a presynaptic localization involving the serotonin transporter (SERT). Neuropsychopharmacology 19 (1998) 265-277
17. LaVoie M.J., and Hastings T.G. Peroxynitrite- and nitrite-induced oxidation of dopamine: implications for nitric oxide in dopaminergic cell loss. J. Neurochem. 73 (1999) 2546-2554
18. Leonardi E.T., and Azmitia E.C. MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac). Neuropsychopharmacology 10 (1994) 231-238
19. Leviel V. The reverse transport of DA, what physiological significance?. Neurochem. Int. 38 (2001) 83-106
20. Li Y., Papke R.L., He Y.J., Millard W.J., and Meyer E.M. Characterization of the neuroprotective and toxic effects of alpha7 nicotinic receptor activation in PC12 cells. Brain Res. 830 (1999) 218-225
21. Mogg A.J., Whiteaker P., McIntosh J.M., Marks M., Collins A.C., and Wonnacott S. Methyllycaconitine is a potent antagonist of alpha-conotoxin-MII-sensitive presynaptic nicotinic acetylcholine receptors in rat striatum. J. Pharmacol. Exp. Ther. 302 (2002) 197-204
22. Morton J. Ecstasy: pharmacology and neurotoxicity. Curr. Opin. Pharmacol. 5 (2005) 79-86
23. O'Callaghan J.P., and Miller D.B. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol. Exp. Ther. 270 (1994) 741-751
24. Park S.U., Ferrer J.V., Javitch J.A., and Kuhn D.M. Peroxynitrite inactivates the human dopamine transporter by modification of cysteine 342: potential mechanism of neurotoxicity in dopamine neurons. J. Neurosci. 22 (2002) 4399-4405
25. Pubill D., Canudas A.M., Pallas M., Camins A., Camarasa J., and Escubedo E. Different glial response to methamphetamine- and methylenedioxymethamphetamine-induced neurotoxicity. Naunyn Schmiedeberg's Arch. Pharmacol. 367 (2003) 490-499
26. Pubill D., Chipana C., Camins A., Pallas M., Camarasa J., and Escubedo E. Free radical production induced by methamphetamine in rat striatal synaptosomes. Toxicol. Appl. Pharmacol. 204 (2005) 57-68
27. Sprague J.E., Everman S.L., and Nichols D.E. An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology 19 (1998) 427-441
28. Stone D.M., Merchant K.M., Hanson G.R., and Gibb J.W. Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat. Neuropharmacology 26 (1987) 1677-1683
29. Thomas D.M., Dowgiert J., Geddes T.J., Francescutti-Verbeem D., Liu X., and Kuhn D.M. Microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines. Neurosci. Lett. 367 (2004) 349-354
30. Turek J.W., Kang C.H., Campbell J.E., Arneric S.P., and Sullivan J.P. A sensitive technique for the detection of the alpha 7 neuronal nicotinic acetylcholine receptor antagonist, methyllycaconitine, in rat plasma and brain. J. Neurosci. Methods 61 (1995) 113-118
31. Zoli M., Moretti M., Zanardi A., McIntosh J.M., Clementi F., and Gotti C. Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum. J. Neurosci. 22 (2002) 8785-8789